These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

431 related articles for article (PubMed ID: 15331931)

  • 1. Combined therapy of cilazapril and losartan has no additive effects in ameliorating adriamycin-induced glomerulopathy.
    Kim HJ; Ryu JH; Han SW; Park IK; Paik SS; Park MH; Paik DJ; Chung HS; Kim SW; Lee JU
    Nephron Physiol; 2004; 97(4):p58-65. PubMed ID: 15331931
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of angiotensin converting enzyme inhibitor, angiotensin II type I receptor blocker and their combination on postinfarcted ventricular remodeling in rats.
    Zhang RY; Wang LF; Zhang L; Meng XN; Li SJ; Wang WR
    Chin Med J (Engl); 2006 Apr; 119(8):649-55. PubMed ID: 16635409
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Renin-angiotensin system blockade prevents the increase in plasma transforming growth factor beta 1, and reduces proteinuria and kidney hypertrophy in the streptozotocin-diabetic rat.
    Erman A; Veksler S; Gafter U; Boner G; Wittenberg C; van Dijk DJ
    J Renin Angiotensin Aldosterone Syst; 2004 Sep; 5(3):146-51. PubMed ID: 15526251
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Relativity of nuclear factor-kappaB (P65/Rel-A) and angiotensin II type 1 receptor expression in early stage of lesions of adriamycin nephrosis in young rats and the effects of intervention].
    Ma H; Li Z; Meng QH; Li XH; Wang XH; Li H; Li WW
    Zhonghua Er Ke Za Zhi; 2004 Apr; 42(4):275-9. PubMed ID: 15157388
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Low-dose dual blockade of the renin-angiotensin system improves tubular status in non-diabetic proteinuric patients.
    Renke M; Tylicki L; Rutkowski P; Wojnarowski K; Lysiak-Szydlowska W; Rutkowski B
    Scand J Urol Nephrol; 2005; 39(6):511-7. PubMed ID: 16303729
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Protective effects of blocking renin-angiotensin system on the progression of renal injury in glomerulosclerosis.
    Ji Z; Huang C; Liang C; Chen B; Chen S; Sun W
    Cell Mol Immunol; 2005 Apr; 2(2):150-4. PubMed ID: 16191423
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dual blockade of the renin-angiotensin-aldosterone system with high-dose angiotensin-converting enzyme inhibitor for nephroprotection: an open, controlled, randomized study.
    Tylicki L; Renke M; Rutkowski P; Larczyński W; Aleksandrowicz E; Lysiak-Szydlowska W; Rutkowski B
    Scand J Urol Nephrol; 2008; 42(4):381-8. PubMed ID: 19230172
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Diuretic uptitration with half dose combined ACEI + ARB better decreases proteinuria than combined ACEI + ARB uptitration.
    Esnault VL; Ekhlas A; Nguyen JM; Moranne O
    Nephrol Dial Transplant; 2010 Jul; 25(7):2218-24. PubMed ID: 20106824
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Blocking angiotensin II ameliorates proteinuria and glomerular lesions in progressive mesangioproliferative glomerulonephritis.
    Nakamura T; Obata J; Kimura H; Ohno S; Yoshida Y; Kawachi H; Shimizu F
    Kidney Int; 1999 Mar; 55(3):877-89. PubMed ID: 10027924
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of dual blockade of renin-angiotensin system in type 2 diabetes mellitus patients with diabetic nephropathy.
    Krairittichai U; Chaisuvannarat V
    J Med Assoc Thai; 2009 May; 92(5):611-7. PubMed ID: 19459520
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Angiotensin receptor blocker reduces proteinuria independently of blood pressure in children already treated with Angiotensin-converting enzyme inhibitors.
    Seeman T; Pohl M; Misselwitz J; John U
    Kidney Blood Press Res; 2009; 32(6):440-4. PubMed ID: 20016211
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Adding a statin to a combination of ACE inhibitor and ARB normalizes proteinuria in experimental diabetes, which translates into full renoprotection.
    Zoja C; Corna D; Gagliardini E; Conti S; Arnaboldi L; Benigni A; Remuzzi G
    Am J Physiol Renal Physiol; 2010 Nov; 299(5):F1203-11. PubMed ID: 20719975
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Renin angiotensin system blockade ameliorates lead nephropathy.
    Ng HY; Tain YL; Lee YT; Hsu CY; Chiou TT; Huang PC; Lee CT
    Biochem Biophys Res Commun; 2013 Aug; 438(2):359-63. PubMed ID: 23896603
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of renin-angiotensin-aldosterone system triple blockade on non-diabetic renal disease: addition of an aldosterone blocker, spironolactone, to combination treatment with an angiotensin-converting enzyme inhibitor and angiotensin II receptor blocker.
    Furumatsu Y; Nagasawa Y; Tomida K; Mikami S; Kaneko T; Okada N; Tsubakihara Y; Imai E; Shoji T
    Hypertens Res; 2008 Jan; 31(1):59-67. PubMed ID: 18360019
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Angiotensin-converting enzyme inhibition and AT1 receptor blockade modify the pressure-natriuresis relationship by additive mechanisms in rats with human renin and angiotensinogen genes.
    Mervaala E; Dehmel B; Gross V; Lippoldt A; Bohlender J; Milia AF; Ganten D; Luft FC
    J Am Soc Nephrol; 1999 Aug; 10(8):1669-80. PubMed ID: 10446934
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Regression of glomerulosclerosis with high-dose angiotensin inhibition is linked to decreased plasminogen activator inhibitor-1.
    Ma LJ; Nakamura S; Aldigier JC; Rossini M; Yang H; Liang X; Nakamura I; Marcantoni C; Fogo AB
    J Am Soc Nephrol; 2005 Apr; 16(4):966-76. PubMed ID: 15728787
    [TBL] [Abstract][Full Text] [Related]  

  • 17. No impact of hyperkalaemia with renin-angiotensin system blockades in maintenance haemodialysis patients.
    Han SW; Won YW; Yi JH; Kim HJ
    Nephrol Dial Transplant; 2007 Apr; 22(4):1150-5. PubMed ID: 17255126
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Renoprotective effect of early inhibition of the renin-angiotensin system in renal transplant recipients.
    Montanaro D; Gropuzzo M; Tulissi P; Vallone C; Boscutti G; Mioni R; Risaliti A; Baccarani U; Adani GL; Sainz M; Bresadola F; Mioni G
    Transplant Proc; 2005 Mar; 37(2):991-3. PubMed ID: 15848600
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [The effects of renin-angiotensin system blockade on the liver steatosis in rats on long-term high-fat diet].
    Chen YH; Yuan L; Chen YY; Qi CJ
    Zhonghua Nei Ke Za Zhi; 2008 Mar; 47(3):197-201. PubMed ID: 18785501
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Triple pharmacological blockade of the renin-angiotensin-aldosterone system in nondiabetic CKD: an open-label crossover randomized controlled trial.
    Tylicki L; Rutkowski P; Renke M; Larczyński W; Aleksandrowicz E; Lysiak-Szydlowska W; Rutkowski B
    Am J Kidney Dis; 2008 Sep; 52(3):486-93. PubMed ID: 18423812
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.